Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Home Monitoring Guided Oral Anticoagulant
- Development stage
- Unknown
- Lead developer
- Biotronik
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
01
Overview
Home Monitoring Guided Oral Anticoagulant is a device-guided therapeutic strategy developed by Biotronik, Inc. for the management of stroke risk in patients with implanted cardiac devices such as ICDs and CRT-Ds. The strategy utilizes the Biotronik Home Monitoring (HM) system to continuously monitor for atrial fibrillation (AF) and atrial flutter (AFL). When an episode lasting 48 hours or more is detected, the system triggers a notification, and the patient is instructed to initiate oral anticoagulant (OAC) therapy, such as dabigatran, rivaroxaban, or warfarin. If the patient remains free of AF/AFL for a specified duration, the OAC is discontinued. This on-demand approach, investigated in the IMPACT clinical trial, aims to provide targeted anticoagulation during periods of high thromboembolic risk while minimizing the risk of major bleeding associated with continuous OAC use.
- Brand names
- Biotronik Home Monitoring
- Other names
- BIOTRONIK Home Monitoring Guided AnticoagulationHM-guided OACIMPACT protocol
02
Targets
F10 (Factor Xa)F2 (Thrombin)VKORC1 (Vitamin K epoxide reductase complex subunit 1)
Beyond the preview
Go deeper on Home Monitoring Guided Oral Anticoagulant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Home Monitoring Guided Oral Anticoagulant.